C12Y 203/01048
Histone acetyltransferase
Official title: Histone acetyltransferase (2.3.1.48)
C12Y203/01048 (Histone acetyltransferase) appears on 17 US grants and 39 published applications in this corpus.
Search patents in C12Y- Granted patents
- 17
- Published applications
- 39
- Assignees
- 28
- Inventors
- 85
- Latest grant
- 4 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 4 |
| 2005 | 1 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 2 |
| 2014 | 0 | 0 |
| 2015 | 1 | 2 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 2 | 3 |
| 2019 | 1 | 3 |
| 2020 | 3 | 4 |
| 2021 | 2 | 1 |
| 2022 | 1 | 6 |
| 2023 | 1 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
| 2026 | 0 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for epigenome editing4 Feb 2025US 12,215,366 B2Duke University
- Reprogramming cell aging12 Sep 2023US 11,754,551 B2Memorial Sloan Kettering Cancer Center
- Methods and compositions for assessing protein function1 Feb 2022US 11,236,326 B2University of Oregon
- Compositions and methods for epigenome editing26 Oct 2021US 11,155,796 B2Duke University
- Engineered CRISPR-Cas9 nucleases13 Jul 2021US 11,060,078 B2The General Hospital Corporation
- Compositions, systems and methods for programming immune cell function through targeted gene regulation1 Oct 2026US 2026/0297545 A1Duke University
- Fusion proteins for improved gene editing24 Sep 2026US 2026/0286397 A1New York Genome Center, Inc.
- Engineered lysine acyltransferases and methods of use thereof6 Aug 2026US 2026/0226429 A1William Marsh Rice University
- Engineered CasPhi2 Nucleases28 May 2026US 2026/0146241 A1
- Shc enzymes and enzyme variants12 Feb 2026US 2026/0043058 A1Givaudan SA
Most cited
By later US patents
- Engineered CRISPR-Cas9 nucleases50US 9,926,546 B2The General Hospital Corporation · 2018
- Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)25US 10,286,052 B2Immatics Biotechnologies GmbH · 2019
- Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)24US 10,064,924 B2Immatics Biotechnologies GmbH · 2018
- ZA loops of bromodomains23US 7,589,167 B2Mt. Sinai School of Medicine · 2009
- Engineered CRISPR-Cas9 nucleases15US 10,526,591 B2The General Hospital Corporation · 2020